The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk of cancer in its users, stating the main ingredient Ranitidine may be a human carcinogen.

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

In July, a Delaware judge dismissed a request from GSK and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer to ...

Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

which alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer. The agreement was much lower than many analysts and investors had expected, including a projection from JP ...

settlement to resolve tens of thousands of lawsuits in the US over its discontinued heartburn drug Zantac. The company said it had settled with about 80,000 people who brought cases against it in ...